468 related articles for article (PubMed ID: 10944553)
1. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
Bani-Hani K; Martin IG; Hardie LJ; Mapstone N; Briggs JA; Forman D; Wild CP
J Natl Cancer Inst; 2000 Aug; 92(16):1316-21. PubMed ID: 10944553
[TBL] [Abstract][Full Text] [Related]
2. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.
Murray L; Sedo A; Scott M; McManus D; Sloan JM; Hardie LJ; Forman D; Wild CP
Gut; 2006 Oct; 55(10):1390-7. PubMed ID: 16682429
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
4. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
5. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of the cyclin D1 gene in Barrett's esophagus.
Arber N; Lightdale C; Rotterdam H; Han KH; Sgambato A; Yap E; Ahsan H; Finegold J; Stevens PD; Green PH; Hibshoosh H; Neugut AI; Holt PR; Weinstein IB
Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):457-9. PubMed ID: 8781742
[TBL] [Abstract][Full Text] [Related]
7. Potential application of p53 as an intermediate biomarker in Barrett's esophagus.
Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC
Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627
[TBL] [Abstract][Full Text] [Related]
8. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of p53 protein in Barrett's syndrome with malignant transformation.
Fléjou JF; Potet F; Muzeau F; Le Pelletier F; Fékété F; Hénin D
J Clin Pathol; 1993 Apr; 46(4):330-3. PubMed ID: 8496390
[TBL] [Abstract][Full Text] [Related]
10. [Carcinogenesis of Barrett's esophagus].
Endo T; Sugawara N; Shinomura Y
Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
13. Expression of C1q complement component in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Lu J; Lord RV
J Gastrointest Surg; 2010 Aug; 14(8):1207-13. PubMed ID: 20496011
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model.
Kawaura Y; Tatsuzawa Y; Wakabayashi T; Ikeda N; Matsuda M; Nishihara S
J Gastroenterol; 2001 Sep; 36(9):595-600. PubMed ID: 11578062
[TBL] [Abstract][Full Text] [Related]
15. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
16. [Molecular alterations in Barrett's esophagus and adenocarcinoma].
Ozawa S; Ando N; Kitagawa Y; Ueda M; Kitajima M
Nihon Geka Gakkai Zasshi; 1999 Mar; 100(3):235-9. PubMed ID: 10379532
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
18. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
20. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
